-
How to solve the deviation of the round bottle labeling machine
Time of Update: 2022-06-03
However, many friends around me said that the round bottle labeling machine is easy to operate, but in the process of use, there are often problems such as the deviation of the label or the poor quality of the label .
-
Application process of online dust monitoring equipment
Time of Update: 2022-06-03
Short press the function key of the test base or lower the App display screen to actively start the update (the sensor must be stable for a short time, and it is recommended to read the article after the data information is stable) .
-
The first domestically produced small-molecule oral drug for COVID-19 is about to come out. What new opportunities are ushered in for the relevant industry chain?
Time of Update: 2022-06-03
On February 20, 2022, Asymchem announced that the company has recently signed a new batch of related products with customers in the process of continuing to provide contract custom development and production (CDMO) services for a small molecule chemical innovative drug of a pharmaceutical company.
-
What are the precautions for maintaining the labeling machine?
Time of Update: 2022-06-03
3. For example, when cleaning the surface of the equipment, use a brush to remove broken glass and broken label paper on the surface of the equipment, wipe the glue thrown off the table with a damp cloth, and wipe the protective cover with a dry cloth .
-
How to buy an economical UV-Vis spectrophotometer
Time of Update: 2022-06-03
1. The content of economy The economy of UV-Vis spectrophotometer means that the instrument should be of high quality and low price .
An instrument with excellent performance is a good instrument, but the technical indicators and degree of automation of those conventional and popular UV-Vis spectrophotometers are not very high .
-
This week's 45 innovative drugs have new progress!
Time of Update: 2022-06-03
According to the Insight database, Zevecimab is currently in Phase III clinical development globally, and China registered Phase I clinical trials at CDE for the first time this week, targeting patients with chronic kidney disease complicated by systemic inflammation .
-
Consistency Evaluation TOP10 Enterprises Released!
Time of Update: 2022-06-03
Up to now, 105 varieties (141 product specifications) of Yangzijiang Pharmaceutical Group have passed/deemed to have passed the consistency evaluation, of which 25 varieties have passed the first evaluation, and a total of 31 varieties have won the bid for the first five batches of centralized procurement .
-
What are the commonly used labeling methods for labeling machines?
Time of Update: 2022-06-03
This is a technology that needs to maintain continuous operation, so its labeling efficiency is improved, and it is mostly suitable for high-speed and high-speed automatic packaging production lines .
-
Drug Patent Reverse Payment Agreement: What does the Supreme Court's first statement mean? The first scene
Time of Update: 2022-06-03
Osaikang, a generic drug manufacturer of saxagliptin, for the infringement of invention patent rights, the Supreme People's Court of China made it clear for the first time that the drug patent reverse payment agreement may violate the "Anti-Monopoly Law" .
-
"Lancet" sub-issue: One year after the new crown, 71% of patients still have sequelae
Time of Update: 2022-06-03
One year after contracting Covid-19, only 29% of patients fully recovered and 71% had sequelae, the most common sequelae being fatigue, muscle pain, slower body, poor sleep and difficulty breathing For the study, researchers analysed patients from 39 UK National Health Service (NHS) hospitals, including 2320 adult participants discharged between March 7, 2020 and April 18, 2021, of whom 807 Participants (32.
-
The rare disease market continues to heat up. How will the global top 10 pharmaceutical companies by revenue be deployed in 2021?
Time of Update: 2022-06-03
Data source: FiercePharma Johnson & JohnsonJohnson & Johnson Johnson & Johnson has been in the field of rare diseases for many years, and the main orphan drug Darzalex (daratumumab) is used to treat multiple types of multiple myeloma (MM) patients, including first-line treatment of MM patients who cannot receive hematopoietic stem cell transplantation .
-
Insight into the TOP10 of China's Biotech R&D investment in 2021, who can survive the cold winter?
Time of Update: 2022-06-02
However, in recent years, many domestic Biotech companies have commercialized products, and the R&D investment is huge .
486 billion yuan on R&D in 2021, which is also the largest R&D investment among all listed pharmaceutical companies in China .
-
Shanghai pharmaceutical companies trapped in the epidemic: production and research and development are almost shut down, how long can they last?
Time of Update: 2022-06-02
A number of local pharmaceutical companies said that employees in their production departments have been under closed management since the end of March .
There are also many pharmaceutical companies who said that during the epidemic control period, most of their early R&D departments worked from home .
-
These 8 new drugs are on the list of important medical progress in 2021!
Time of Update: 2022-06-02
In terms of pharmacy, 8 new drugs approved in 2021 are on the list , namely Tengsheng Biopharmaceutical Ambavirumab/Romisevirumab, Real Bio Azvudine, Hengrui Medicine Haitrapopaethanolamine, Hisun Pharmaceutical Haibo Maibu, Ascentage Medicine Orebatinib, Chi-Med Sivotinib, Zejing Biopharmaceutical Donafenib Tosylate, and Rongchang Biotech Vidicitumumab .
-
AI + Microecological Therapy Blockbuster: Unknown Jun Acquires Ulcerative Colitis Clinical Pipeline
Time of Update: 2022-06-02
A few days ago, the industry-leading AI+ innovative therapy microecological drug research and development company Wuweijun announced that it has acquired the clinical stage drug pipeline M201 project from Assembly Biosciences, Inc.
-
For Renal Cell Cancer!
Time of Update: 2022-06-02
First-line therapy for advanced renal cell carcinoma (ccRCC) and adjuvant therapy for first-line renal cell carcinoma (RCC) is the first hypoxia-inducible factor (HIF-2α) inhibitor (HIF-2α) approved by the US FDA Screenshot source: Drug Clinical Trial Registration and Information Publicity Platform Belzutifan is an investigational, novel, potent, and selective oral HIF-2α inhibitor currently being evaluated in multiple clinical studies for the treatment of patients with VHL-related renal cell carcinoma, advanced renal cell carcinoma, and advanced solid tumors .
-
CDMO Kaituo Biotech in the field of nucleic acid technology completes tens of millions of US dollars in Series A financing
Time of Update: 2022-06-02
This round of funds will be used for the construction of plasmid and mRNA industrialization bases and the construction of new technology research and development platforms, to continuously improve the capability and scale of the one-stop CDMO service platform, and to empower Chinese and global partners .
-
Pfizer and AZ topped the list, and Baekje entered the top 10!
Time of Update: 2022-06-02
On April 22, IDEA Pharma released the global pharmaceutical innovation and invention index list, Pfizer and AZ ranked first in the two lists respectively; BeiGene and Takeda became the two companies that rose the most; BioNTech, UCB, Horizon, Shionogi is this year's newcomer .
-
New crown vaccine review, how effective are the 5 major vaccines?
Time of Update: 2022-06-01
Figure 1 shows the time and country when the main new coronavirus mutant strains were first reported, from "2021 New Coronary Virus Mutation, Cross-species Transmission, and a Review of Hot Spots in Vaccine and Drug Research" About the new crown vaccineAbout the new crown vaccine On December 2, 2020, the world's first mRNA vaccine BNT162b2 received emergency use authorization in the UK .
-
Nature: LAG-3, the next outlet?
Time of Update: 2022-06-01
At the LAG3 Targeted Drug Development Summit held in January this year, Paul Moore from MacroGenics said that the PD-1×LAG-3 bispecific antibody Tebotelimab can simultaneously block the growth of a single T cell.
